CTLA4 and neoplasm: Despite the success of checkpoint inhibitors inducing durable responses through the targeting of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein/ligand 1 (PD-1/L1), some patients with stable or otherwise undetectable disease can relapse and suddenly lose tumor control [3, 4].